Companies
Healthcare companies with their tickers, drugs by stage and next published catalyst. Each company page lists its drugs, filings and sources.
Every drug and its trials: Drug Database
Results
| Company | Tickers | Drugs | By stage | Next catalyst |
|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. | FDMT | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| 89bio, Inc. | None listed | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| ABBOTT LABORATORIES | ABT | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| AbbVie Inc.Tracked | ABBV | 3131 not yet reviewed | Phase 2/3: 3 · Phase 3: 14 · Approved: 14 | None scheduled |
| Abivax S.A. | ABVX, AAVXF | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| ACADIA PHARMACEUTICALS INC | ACAD | 22 not yet reviewed | Phase 3: 2 | None scheduled |
| Acer Therapeutics Inc. | None listed | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| ACHIEVE LIFE SCIENCES, INC. | ACHV | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| Actinium Pharmaceuticals, Inc. | ATNM | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| ADARx Pharmaceuticals, Inc. | ADRX | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| ADC Therapeutics SA | ADCT | 11 not yet reviewed | Approved: 1 | None scheduled |
| AGIOS PHARMACEUTICALS, INC. | AGIO | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| Akebia Therapeutics, Inc. | AKBA | 11 not yet reviewed | Approved: 1 | None scheduled |
| Akero Therapeutics, Inc. | None listed | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| ALCON INC | ALC | 22 not yet reviewed | Approved: 2 | None scheduled |
| Aldeyra Therapeutics, Inc. | ALDX | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| Alkermes plc. | ALKS | 22 not yet reviewed | Approved: 2 | None scheduled |
| ALNYLAM PHARMACEUTICALS, INC. | ALNY | 22 not yet reviewed | Phase 3: 2 | None scheduled |
| Altimmune, Inc. | ALT | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| ALUMIS INC. | ALMS | 11 not yet reviewed | Phase 3: 1 | None scheduled |
| Alvotech | ALVO, ALVOW | 44 not yet reviewed | Phase 3: 4 | None scheduled |
| ALX ONCOLOGY HOLDINGS INC | ALXO | 11 not yet reviewed | Phase 2/3: 1 | None scheduled |
| AMGEN INCTracked | AMGN | 1212 not yet reviewed | Phase 3: 6 · Approved: 6 | None scheduled |
| AMICUS THERAPEUTICS, INC. | None listed | 22 not yet reviewed | Phase 3: 2 | None scheduled |
| Amneal Pharmaceuticals, Inc. | AMRX | 11 not yet reviewed | Approved: 1 | None scheduled |
Drug counts leave out retired records and include drugs marked “Not yet reviewed”, which are listed from FDA or ClinicalTrials.gov records an editor has not checked yet. Catalyst dates come from company and FDA disclosures and can change.
Company data: SEC EDGAR and HealthTrade editors. Trial data: ClinicalTrials.gov. FDA data provided by the U.S. Food and Drug Administration. Nothing here is investment advice.